Kigabeq (Vigabatrin)

Vigabatrin irreversibly inhibits the enzyme GABA transaminase, which normally degrades the inhibitory neurotransmitter GABA. By blocking this enzyme, vigabatrin raises GABA levels in the brain, enhancing neuronal inhibition and decreasing the likelihood of abnormal electrical discharges that cause seizures.

The appropriate dose of Kigabeq is individualized by the prescribing clinician based on factors such as the patient’s age, weight, seizure type, response to therapy, and renal function. Dosage adjustments are made according to clinical response and tolerability, and patients should follow the prescriber’s instructions exactly.

The pregnancy safety category for vigabatrin is listed as unknown. Because animal studies have shown potential risks and human data are limited, clinicians usually weigh the benefits against possible fetal risks before prescribing. Breastfeeding is also not well studied, so caution is advised and alternative treatments may be considered.

To request Kigabeq, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and the necessary import documentation.

Unlike many antiepileptics that modulate sodium channels or calcium influx, vigabatrin uniquely increases GABA levels by inhibiting its breakdown. This mechanism can be advantageous for patients who have not responded to drugs such as carbamazepine or lamotrigine, but it carries a specific risk of visual field loss that is not typical of those alternatives.

Kigabeq should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in areas with high humidity or extreme temperature fluctuations.

Kigabeq is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not chewed or crushed. Dosing times are typically spaced evenly throughout the day as directed by the prescriber, and it may be taken with or without food depending on individual tolerance.

The most critical safety concerns include irreversible peripheral visual field constriction, which may be permanent, and the emergence of depressive symptoms or suicidal thoughts. Patients should report any sudden changes in vision, mood, or mental status to their healthcare provider immediately.

Kigabeq is contraindicated in patients with known hypersensitivity to vigabatrin or any of the tablet’s excipients. It should also be avoided in individuals with pre‑existing severe visual field defects, uncontrolled depression, or those who cannot undergo regular visual monitoring.